Cliff Asness's REGN Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 995,710 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $768.52 M, representing 0.40% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 606,612 shares. Largest reduction occurred in Q2 2018, reducing 178,740 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +274,356 | Add 38.03% | 995,710 | $771.83 |
| Q3 2025 | +606,612 | Add 528.67% | 721,354 | $562.27 |
| Q2 2025 | -121,208 | Reduce 51.37% | 114,742 | $520.10 |
| Q1 2025 | +28,865 | Add 13.94% | 235,950 | $630.07 |
| Q4 2024 | -18,449 | Reduce 8.18% | 207,085 | $710.32 |
| Q3 2024 | +36,243 | Add 19.15% | 225,534 | $1043.00 |
| Q2 2024 | +6,839 | Add 3.75% | 189,291 | $1049.03 |
| Q1 2024 | -13,429 | Reduce 6.86% | 182,452 | $960.42 |
| Q4 2023 | +5,712 | Add 3.00% | 195,881 | $877.33 |
| Q3 2023 | -29,481 | Reduce 13.42% | 190,169 | $822.96 |
| Q2 2023 | -21,124 | Reduce 8.77% | 219,650 | $705.96 |
| Q1 2023 | -68,381 | Reduce 22.12% | 240,774 | $821.21 |
| Q4 2022 | -121,146 | Reduce 28.15% | 309,155 | $715.56 |
| Q3 2022 | -120,115 | Reduce 21.82% | 430,301 | $688.87 |
| Q2 2022 | +41,635 | Add 8.18% | 550,416 | $587.14 |
| Q1 2022 | +59,162 | Add 13.16% | 508,781 | $698.42 |
| Q4 2021 | +173,586 | Add 62.89% | 449,619 | $631.52 |
| Q3 2021 | +81,918 | Add 42.20% | 276,033 | $605.18 |
| Q2 2021 | -96,546 | Reduce 33.22% | 194,115 | $546.61 |
| Q1 2021 | -63,244 | Reduce 17.87% | 290,661 | $473.14 |
| Q4 2020 | -111,199 | Reduce 23.91% | 353,905 | $472.00 |
| Q3 2020 | +103,282 | Add 28.54% | 465,104 | $559.78 |
| Q2 2020 | -23,706 | Reduce 6.15% | 361,822 | $615.81 |
| Q1 2020 | +42,468 | Add 12.38% | 385,528 | $465.21 |
| Q4 2019 | +48,009 | Add 16.27% | 343,060 | $375.17 |
| Q3 2019 | -55,846 | Reduce 15.92% | 295,051 | $275.32 |
| Q2 2019 | -32,960 | Reduce 8.59% | 350,897 | $313.00 |
| Q1 2019 | +152,469 | Add 65.89% | 383,857 | $409.63 |
| Q4 2018 | +47,207 | Add 25.63% | 231,388 | $373.50 |
| Q3 2018 | +71,623 | Add 63.63% | 184,181 | $404.04 |
| Q2 2018 | -178,740 | Reduce 61.36% | 112,558 | $344.99 |
| Q1 2018 | +197,650 | Add 211.06% | 291,298 | $344.36 |
| Q4 2017 | +45,447 | Add 94.29% | 93,648 | $375.96 |
| Q3 2017 | +42,577 | Add 757.06% | 48,201 | $447.13 |
| Q2 2017 | -3,181 | Reduce 36.13% | 5,624 | $491.11 |
| Q1 2017 | +5,884 | Add 201.44% | 8,805 | $387.51 |
| Q4 2016 | -531 | Reduce 15.38% | 2,921 | $367.00 |
| Q3 2016 | +1,167 | Add 51.07% | 3,452 | $402.09 |
| Q2 2016 | -8,806 | Reduce 79.40% | 2,285 | $349.23 |
| Q1 2016 | -34,259 | Reduce 75.54% | 11,091 | $360.47 |
| Q4 2015 | +24,164 | Add 114.06% | 45,350 | $542.87 |
| Q3 2015 | +4,382 | Add 26.08% | 21,186 | $465.12 |
| Q2 2015 | +3,157 | Add 23.13% | 16,804 | $510.12 |
| Q1 2015 | +4,974 | Add 57.35% | 13,647 | $451.45 |
| Q4 2014 | +2,734 | Add 46.03% | 8,673 | $410.24 |
| Q3 2014 | -11,100 | Reduce 65.14% | 5,939 | $360.50 |
| Q2 2014 | -15,000 | Reduce 46.82% | 17,039 | $282.47 |
| Q1 2014 | -2,600 | Reduce 7.51% | 32,039 | $300.29 |
| Q4 2013 | -8,077 | Reduce 18.91% | 34,639 | $275.24 |
| Q3 2013 | +11,305 | Add 35.99% | 42,716 | $312.88 |
| Q2 2013 | +31,411 | Add 0.00% | 31,411 | $224.89 |
| Q4 2012 | +17,120 | Add 0.00% | 17,120 | $171.09 |
Cliff Asness's Regeneron Pharmaceuticals Investment FAQs
Cliff Asness first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q4 2012, acquiring 17,120 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Regeneron Pharmaceuticals, Inc. (REGN) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q3 2025, adding 721,354 shares worth $405.6 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 995,710 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $768.52 M.
As of the Q4 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.40% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 995,710 shares, as reported at the end of Q4 2025.